RxDoctor Payments Data

Kathleen Brooks

Psychiatric/Mental Health · Brooklyn, NYNPI 1518108554

Payments from drug & device makers

$9,126in general payments, 2019–2025

Across 301 payments — averaging $30.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • Alkermes, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$814
  • Johnson & Johnson$803
  • E.r. Squibb & Sons, L.L.C.$778
  • Teva Pharmaceuticals USA, Inc.$722
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$9,01799%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,126 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$21,170
Medicare patients
26
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$183,467
Risperdal ConstaRisperidone Microspheres51$57,722
Aripiprazole71$6,013
Venlafaxine Hcl ErVenlafaxine Hcl103$2,546
Haloperidol Decanoate44$1,894
Bupropion XlBupropion Hcl114$1,697
Clomipramine Hcl18$1,448
Trifluoperazine Hcl13$1,378
Quetiapine Fumarate173$1,365
Trazodone Hcl200$1,318
Mirtazapine75$826
Olanzapine93$801
Fluvoxamine Maleate14$736
Benztropine Mesylate85$713
Escitalopram Oxalate104$711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$2,037$183,46723 claims
Johnson & JohnsonRisperdal Consta$803$57,72251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →